Immunome (IMNM) filed a prospectus late Friday for the sale of 1.8 million shares by selling shareholders from time to time.
The shares covered in the prospectus were issued under the stock issuance agreement on Oct. 25, the company said in a filing with the US Securities and Exchange Commission.
Immunome said it will not receive any proceeds from the sale of shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments